Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on December 24th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $93.69 on Thursday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The firm has a fifty day simple moving average of $97.32 and a 200-day simple moving average of $100.53. The stock has a market capitalization of $138.89 billion, a price-to-earnings ratio of 50.10, a PEG ratio of 1.67 and a beta of 0.67. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra in a cash-and-stock deal valued around $14.5–$15 billion, adding thrombectomy and neurovascular capabilities that materially expand its cardiovascular portfolio and address high-growth adjacencies. The transaction is the primary catalyst for today’s positive move. Boston Scientific to buy Penumbra in deal valued at $14.5 billion
• Positive Sentiment: Regulatory and product wins strengthen growth outlook: FDA clearance for the Farapoint PFA catheter and CE mark for the Embold detachable coil expand Boston Scientific’s EP and neurovascular product mix—supporting higher-margin revenue expectations cited by analysts. Boston Scientific wins FDA nod for Farapoint PFA catheter
• Positive Sentiment: Analyst reaffirmations: Multiple firms reiterated Buy ratings, citing diversified growth engines (PFA, thrombectomy, neurovascular) and strong execution—these endorsements help support investor confidence after the deal. Farapoint PFA Approval Strengthens EP Ecosystem and Supports Buy Rating
• Positive Sentiment: Bolt-on M&A and expansion: Boston Scientific is acquiring Valencia (urinary incontinence) and planning a Maple Grove facility expansion—incremental moves that broaden addressable markets and manufacturing capacity. Boston Scientific to buy incontinence device maker Valencia
• Neutral Sentiment: Investor presentation and conference activity: Boston Scientific presented at the J.P. Morgan Healthcare Conference; management commentary (growth drivers and execution cadence) will be parsed for guidance/assumptions but hasn’t yet changed financial targets. J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Local expansion news: Planned Maple Grove expansion is constructive for capacity and jobs but is a longer-term operational item. Boston Scientific plans expansion in Maple Grove
• Negative Sentiment: Insider selling: A recent reported sale of BSX stock by Rep. Gilbert Ray Cisneros, Jr. may raise short-term sentiment concerns for some investors, though political/optics-driven trades are not always informative about fundamentals. Boston Scientific Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 93,095 shares of company stock worth $9,305,450 over the last quarter. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BSX. Steph & Co. bought a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific during the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp boosted its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at about $26,000. Finally, Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Leerink Partners upped their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. BTIG Research restated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research note on Friday, November 21st. Finally, Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average price target of $125.21.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.